Insulet Corp
Закрыт
СекторЗдравоохранение
149.51 0.33
Обзор
Изменение цены акций
24 ч
Мин.
148.69
Макс.
150.13
Доход | -11M 91M |
|---|---|
Продажи | -22M 762M |
P/E Средняя по отрасли | 35.482 49.052 |
Прибыль на акцию | 1.3 |
Рентабельность продаж | 11.96 |
Сотрудники | 5,400 |
EBITDA | -23M 154M |
Рекомендации | Активная покупка |
|---|---|
Прогноз на 12 месяцев | +53.21% upside |
Следующий отчет о доходах | 6 авг. 2026 г. |
|---|
Рыночная капитализация | -1.4B 10B |
|---|---|
Предыдущая цена открытия | 149.18 |
Предыдущая цена закрытия | 149.51 |
Новостные настроения
By Acuity
68%
32%
308 / 342 Рейтинг в Healthcare
Insulet Corp График
Прошлые результаты не являются надежным индикатором будущих результатов.
О компании Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.